Defining Cancer Drug Development Part I: A Discussion with FDA's Pazdur
This article was originally published in RPM Report
Executive Summary
FDA’s cancer czar Richard Pazdur is a lightning rod for critics who say he’s keeping potentially life-saving drugs off the market because regulatory standards are too high. He says just look at the data.
You may also be interested in...
Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
When Richard Pazdur discussed ideas for a National Cancer Policy at an IoM event, one theme was unmistakable: if sponsors really believe what they say about targeted therapies for cancer, they should aim high with their clinical trial designs and endpoints.
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
Development time is the same for cancer drugs cleared under subpart H and under the regular approval pathway, according to a study in the Journal of Clinical Oncology. Article calls attention to idea that cancer drugs may need new, more favorable FDA policies on surrogate markers.